Researchers say inflammation as a treatment target still important despite neutral results of ZEUS trial

Coverage, in order

1. 4d ago
   
   AHA Newsroom indie study

   Researchers say inflammation as a treatment target still important despite neutral results of ZEUS trial

   Research Highlights: Inflammation is a target for cardiovascular risk reduction. However, there are currently limited options to reduce inflammation among people with chronic kidney disease. The Ziltivekimab Cardiovascular Outcomes Study (ZEUS) was...

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.